Rectify Pharmaceuticals - Crunchbase Company Profile & Funding

Q: Who invested in Rectify Pharmaceuticals?

Rectify Pharmaceuticals has 4 investors including Forbion Capital Partners And Longwood Fund.

Q: How much funding has Rectify Pharmaceuticals raised to date?

Rectify Pharmaceuticals has raised obfuscated.

Overview

Rectify Pharmaceuticals

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+2 more milestones

See more interactive data and historical milestones on desktop for the best experience

About Rectify Pharmaceuticals

CB Rank

23919

Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.

Founded

obfuscation

Private

Series A

Cambridge, Massachusetts, United States

11-50

rectifypharma.com/

Biotechnology

Life Science

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Key People

Rajesh Devraj: President and Chief Executive Officer
Past Role: Atlas Venture, Entrepreneur in Residence
Jonathan Moore: Founder and Chief Scientific Officer

Details

Legal Name

Rectify Pharmaceuticals, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Jonathan Moore

About the Company

Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.

Contact Email

info@rectifypharma.com

Predictions & Insights

Growth Insight

See this Growth Insight

Rectify Pharmaceuticals is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

RTY-694

An orally available dual-targeted Positive Functional Modulator that improves bile composition and enhances bile flow by modulating ABCB4 and BSEP transporters.

RTY-822

An orally administered Positive Functional Modulator targeting ABCC6 to increase plasma inorganic pyrophosphate levels, reduce vascular calcification, and improve kidney function in chronic kidney disease.

Research & Development

Rectify Pharmaceuticals is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A
obfuscated obfuscation	Series A - Rectify Pharmaceuticals	4	obfuscated obfuscation	Atlas Venture, Forbion Capital Partners, Longwood Fund, Omega Funds	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Forbion Capital Partners	Yes	Series A - Rectify Pharmaceuticals	Marco Boorsma
Forbion Capital Partners	Yes	Series A - Rectify Pharmaceuticals	Marco Boorsma
Forbion Capital Partners	Yes	Series A - Rectify Pharmaceuticals	Marco Boorsma
Forbion Capital Partners	Yes	Series A - Rectify Pharmaceuticals	Marco Boorsma
Forbion Capital Partners	Yes	Series A - Rectify Pharmaceuticals	Marco Boorsma